Simultaneously defining cell phenotypes, cell cycle, and chromatin modifications at single-cell resolution

FASEB Journal

Volumn 27, Issue 7, 2013, Pages 2667-2676

  Chambliss, Allison B ^a,b   Wu, Pei Hsun ^a,b   Chen, Wei Chiang ^a,b   Sun, Sean X ^a,b   Wirtz, Denis ^a,b  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Epigenetics; High throughput; Microscopy

Indexed keywords

DNA; F ACTIN; HISTONE H3;

ACTIN FILAMENT; ANIMAL CELL; ARTICLE; CELL CYCLE; CELL CYCLE PHASE; CELL SHAPE; CELL STRUCTURE; CELL SYNCHRONIZATION; CHROMATIN; CONTROLLED STUDY; DNA CONTENT; EPIGENETICS; HISTONE ACETYLATION; MICROSCOPY; MORPHOLOGY; MOUSE; NONHUMAN; NUCLEAR SIZE; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL;

EPIGENETICS; HIGH-THROUGHPUT; MICROSCOPY;

ACETYLATION; ACTINS; ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; CELL SHAPE; CHROMATIN; CULTURE MEDIA, SERUM-FREE; DNA; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; MICE; MICROSCOPY, FLUORESCENCE; MYOBLASTS; REPRODUCIBILITY OF RESULTS; SINGLE-CELL ANALYSIS;

EID: 84879638500     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.12-227108     Document Type: Article

References (22)

1. Strahl, B. D., and Allis, C. D. (2000) The language of covalent histone modifications. Nature 403, 41-45 (Pubitemid 30038513)
2. Zhang, K., and Dent, S. Y. R. (2005) Histone modifying enzymes and cancer: going beyond histones. J. Cell. Biochem. 96, 1137-1148 (Pubitemid 41681856)
3. De Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S., and van Kuilenburg, A. B. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370, 737-749 (Pubitemid 36399066)
4. Esteller, M. (2008) Molecular origins of cancer: epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159
5. Sharma, S., Kelly, T. K., and Jones, P. A. (2010) Epigenetics in cancer. Carcinogenesis 31, 27-36
6. Portela, A., and Esteller, M. (2010) Epigenetic modifications and human disease. Nat. Biotechnol. 28, 1057-1068
7. Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., and Kurdistani, S. K. (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262-1266 (Pubitemid 40943093)
8. Witt, O., Deubzer, H. E., Milde, T., and Oehme, I. (2009) HDAC family: What are the cancer relevant targets? Cancer Lett. 277, 8-21
9. Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., Iyer, N. G., Perez-Rosado, A., Calvo, E., Lopez, J. A., Cano, A., Calasanz, M. J., Colomer, D., Piris, M. A., Ahn, N., Imhof, A., Caldas, C., Jenuwein, T., and Esteller, M. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37, 391-400
10. Bolden, J. E., Peart, M. J., and Johnstone, R. W. (2006) Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784 (Pubitemid 44348499)
11. Minucci, S., and Pelicci, P. G. (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51 (Pubitemid 43054973)
12. Chavez-Blanco, A., Segura-Pacheco, B., Perez-Cardenas, E., Taja-Chayeb, L., Cetina, L., Candelaria, M., Cantu, D., Gonzalez-Fierro, A., Garcia-Lopez, P., Zambrano, P., Perez-Plasencia, C., Cabrera, G., Trejo-Becerril, C., Angeles, E., and Duenas-Gonzalez, A. (2005) Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol. Cancer 4, 22
13. Ronzoni, S., Faretta, M., Ballarini, M., Pelicci, P., and Minucci, S. (2005) New method to detect histone acetylation levels by flow cytometry. Cytometry A 66A, 52-61 (Pubitemid 40868919)
14. Esteller, M. (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8, 286-298
15. Dasgupta, A., Sharma, P., and Haque, S. J. (2006) Promoter-specific chromatin immunoprecipitation: A novel method to study the epigenetics of brain tumor cells. Neuro-Oncol. 8, 395-395
16. Heppner, G. H. (1984) Tumor heterogeneity. Cancer Res. 44, 2259-2265
17. Marusyk, A., and Polyak, K. (2010) Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 1805, 105-117
18. Chen, W. C., Wu, P. H., Phillip, J. M., Khatau, S. B., Choi, J. M., Dallas, M. R., Konstantopoulos, K., Sun, S. X., Lee, J. S., Hodzic, D., and Wirtz, D. (2013) Functional interplay between the cell cycle and cell phenotypes. Integr. Biol. 5, 523-534
19. Wu, P. H., Hung, S. H., Ren, T., Shih, I. M., and Tseng, Y. (2010) Cell cycle-dependent alternation in NAC1 nuclear body dynamics and morphology. Phys. Biol. 8, 015005
20. Lazarides, E., and Weber, K. (1974) Actin antibody: the specific visualization of actin filaments in non-muscle cells. Proc. Natl. Acad. Sci. U. S. A. 71, 2268-2272
21. Holland, A. J., and Cleveland, D. W. (2012) Losing balance: the origin and impact of aneuploidy in cancer. EMBO Rep. 13, 501-514
22. Chang, J., Varghese, D. S., Gillam, M. C., Peyton, M., Modi, B., Schiltz, R. L., Girard, L., and Martinez, E. D. (2012) Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Brit. J. Cancer 106, 116-125